The Liver Meeting 2014

Authors:

Nezam Hassan Afdhal,¹ Graham Foster,² Jean-Michel Pawlotsky^3,4

1. Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
2. Queen Mary University of London, Institute of Cell and Molecular Science, London, UK
3. National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France
4. INSERM U955, Créteil, France
*Correspondence to [email protected]

Disclosure:

Nezam H. Afdhal has received research support (within last 2 years) for HCV studies from Merck, Vertex, Gilead, AbbVie and BMS; is a consultant and/or advisory board member for Merck, Gilead, Echosens, Glaxo Smith Kline, Ligand, Springbank, Kadmon, Jannsen, AbbVie, Achillion, and Sandhill Scientific; holds stock or stock options with Springbank; and is the Editor of the Journal of Viral Hepatitis. Graham Foster has received funding from AbbVie, BMS, Boehringer Ingelheim, Gilead, Roche, Merck, Novartis, Springbank, Achillion, Tekmira, and Alnylam. Jean-Michel Pawlotsky has received research grants from Gilead Sciences. He has served as an advisor for  AbbVie, Achillion, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Idenix, Janssen, Merck, Novartis, and Roche.

Acknowledgements:

Medical writing assistance was provided by Dr Caroline Charles (Scilink Medical Writing, Biarritz, France).

Support:

Gilead financial support via an unrestricted educational grant.

Citation:

EMJ Hepatol. 2015;3(Suppl 3):2-19. DOI/10.33590/emjhepatol/10313824. https://doi.org/10.33590/emjhepatol/10313824.

Keywords:

Hepatitis C virus infection, direct-acting antivirals, sofosbuvir, daclatasvir, ledipasvir, GS-5816, simeprevir

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.